Correlation Engine 2.0
Clear Search sequence regions

  • ageusia (1)
  • anosmia (1)
  • brain (5)
  • cohort studies (1)
  • coronavirus (16)
  • female (2)
  • gi tract (1)
  • humans (1)
  • mental health (1)
  • patients (2)
  • risk factors (1)
  • rna viral (2)
  • sars cov (1)
  • serotonin (1)
  • Sizes of these terms reflect their relevance to your search.

    Ten percentage of patients with coronavirus disease (COVID)-19 report having gastrointestinal (GI) symptoms as severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) not only infects the pulmonary but also the GI tract. GI infections including that due to viral infection is known to cause postinfection disorders of gut-brain interaction (DGBI); hence, we wish to review the long-term GI consequences following COVID-19, particularly post-COVID-19 DGBI. At least 12 cohort studies, four of which also included controls documented the occurrence of post-COVID-19 DGBI, particularly IBS following COVID-19. The risk factors for post-COVID-19 DGBI included female gender, symptomatic COVID-19, particularly GI symptoms, the severity of COVID-19, the occurrence of anosmia and ageusia, use of antibiotics and hospitalization during the acute illness, persistent GI symptoms beyond 1 month after recovery, presence of mental health factors, The putative mechanisms for post-COVID-19 DGBI include altered gut motility, visceral hypersensitivity, gut microbiota dysbiosis, GI inflammation, and immune activation, changes in intestinal permeability, and alterations in the enteroendocrine system and serotonin metabolism. Long-term sequelae of SARS-CoV2 infection may persist even after recovery from COVID-19. Patients with COVID-19 are more likely to develop post-COVID-19 IBS than healthy controls. Post-COVID-19 IBS may pose a substantial healthcare burden to society. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.


    Uday C Ghoshal, Ujjala Ghoshal. Gastrointestinal involvement in post-acute Coronavirus disease (COVID)-19 syndrome. Current opinion in infectious diseases. 2023 Oct 01;36(5):366-370

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 37606895

    View Full Text